Neuroendokrine Tumore / endokrine Malignome (inkl. Schilddrüse, Nebennierenkarzinom)| ICD10: C73, C74, C75
Sie befinden sich hier:
Studien offen zur Rekrutierung
COMPETE40 KB
A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
Deutsches NET-Register19,08 KB
Projekt der Arbeitsgemeinschaft Neuroendokrine Gastrointestinale Tumore
ENSAT-Register139 KB
Europäisches Netzwerk für Nebennierentumoren
IDENTIFICATION OF NEW BIOMARKERS FROM NET PATIENTS17,60 KB
IDENTIFICATION OF NEW BIOMARKERS FROM PATIENTS WITH NEUROENDOCRINE CANCER USING LIQUID BIOPSY METHODS
MK-6482-015194 KB
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Assoc
SEQTOR81 KB
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
SORENTO (Camurus)49 KB
A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients with gastroenteropancreatic neuroendocrine tumors